Comparison of the efficacy of entecavir therapy and adefovir for patients with HBeAg positive chronic hepatitis B

Objective:To compare the efficacy and safety of entecavir(ETV) and adefovir(ADV) for the patients with HBeAg positive chronic hepatitis B.Methods: 81 CHB patients with HBeAg positive were treated with daily dose of ETV 0.5 mg(47 patients) or ADV 10 mg(34 patients) randomly for at least 48 weeks.Liver and renal functions were tested,serum HBV DNA,hepatitis B viral markers were detected for all patients before treatment,for 24 weeks,48 weeks treatment,respectively.Adverse drug reactions were observed.Results: At week 24,the normalization of ALT in the two groups was similar(83.0% vs 76.5%,χ2=0.527,P0.05);HBV DNA negative rate in ETV group was significantly higher than that in ADV group(44.7% vs 17.6%,χ2=6.488,P0.05);HBeAg negative rate was similar in the two groups(8.5% vs 5.9%,χ2=0.199,P0.05).At week 48,the normalization of ALT in the two groups was similar(89.4% vs 88.2%,χ2=0.025,P0.05);HBV DNA negative rate in ETV group was significantly higher than that in ADV group(57.4% vs 23.5%,χ2=9.249,P0.05);HBeAg negative rate was similar in the two groups(12.8% vs 11.8%,χ2=0.018,P0.05).There was no serious drug-related adverse reactions and resistent cases during the treatment.Conclusion: ETV is more potent to suppress HBV replication,while the safety profile is comparable to ADV.